Congressionally Directed Medical Research Programs -- Peer Reviewed Alzheimer’s Disease Research Program -- Accelerating Diagnostics for Traumatic Brain Injury Research Award

Funding Agency:
Department of Defense

The intent of the FY20 PRARP ADTBI is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for chronic TBI as they pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY20 PRARP ADTBI mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical end points. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of chronic TBI as it pertains to AD/ADRD as the study endpoint. The FY20 PRARP ADTBI does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to both TBI and AD/ADRD research. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research.

The FY20 PRARP ADTBI encourages applications to consider fluid-based, imaging-based, retinal or wearable devices as potential diagnostics. Demonstration of access to an already existing cohort or provision of a plan that demonstrates expedited participant accrual is required. In addition, suitability of the existing cohort or participant population must be detailed. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY20 PRARP ADTBI applications must be Impactbased.


  • REQUIRED Pre-application Submission Deadline:  June 22, 2020
  • Full Application Submission Deadline:  July 21, 2020

Agency Website

Areas of Interest

FY20 PRARP ADTBI Overarching Challenge: The Overarching Challenge below is specific to the FY20 PRARP ADTBI. Applicants to the FY20 PRARP ADTBI must address the Overarching Challenge below.

  • Diagnostics and Prognostics: The need for technologies, tests, surveys, questionnaires, devices, biomarkers, or analyses to detect TBI sequelae for AD/ADRD utilizing new and/or pre-existing datasets.

FY20 PRARP ADTBI Focus Area: The Focus Area below is specific to the FY20 PRARP ADTBI and must be addressed as part of the application process.

  • Biomarkers: Development of methods to diagnose, prognose, or characterize neurological changes or risk/resiliency factors associated with TBI and subsequent AD/ADRD.

Eligibility Requirements

The named PI must be at or above the level of an assistant professor (or equivalent). Each investigator may be named on only one FY20 PRARP ADTBI application as a PI. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The Initiating PI must be at or above the level of an assistant professor (or equivalent). Each named Co-PI must be at or above the level of an assistant professor (or equivalent). Each investigator may be named on only one FY20 PRARP RPA application as the Initiating PI. There are no limitations on the number of applications that an Initiating PI can be listed as a CoPI.



Amount Description

The anticipated total costs budgeted for the entire period of performance for an FY20 PRARP ADTBI Award will not exceed $2,800,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type



Junior Faculty


Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

June 22, 2020